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Table. Base-Case Estimates of 5-Year Treatment Costs and Quality-Adjusted
Life-Years
Treatment
Strategy Germany Italy France Spain
The
Netherlands
Universal
Ticagrelor
Costs (V) 19,611 19,806 19,287 19,355 19,058
QALYs 3.919 3.858 3.764 3.822 3.910
PRA-Driven
Ticagrelor
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S24 and 72h after the switch, and veriﬁed through standard Light Transmission
Aggregometry (LTA).
Results: No relevant difference in platelet aggregation between the two study arms
was observed at baseline (p¼0.256). Residual platelet aggregation measured using
MEA was signiﬁcantly reduced in both arms 2h after the ﬁrst administration of TICA
(both p<0.001). Most interestingly, no difference in aggregation was found 2 hours
after the switch to TICA (17672 vs 18160 AUmin, p¼0.281). Similar ﬁndings
were conﬁrmed with LTA.
Conclusions: Switching from ongoing CLO therapy to TICA without a loading dose
is safe and is not associated to a lower degree of PLT inhibition in patients with ACS.
Larger trials are needed to conﬁrm the present results on a clinical endpoint, as
incidence of bleedings.Costs (V) 19,195 19,168 18,965 18,851 18,633
QALYs 3.910 3.849 3.756 3.814 3.902
ICER vs. PRA-
Driven
Ticagrelor
46,222 70,889 40,250 63,000 53,125
Universal
Prasugrel
Costs (V) 19,636 19,373 19,059 19,034 18,934
QALYs 3.875 3.815 3.722 3.780 3.867
PRA-Driven
Prasugrel
Costs (V) 19,205 18,984 18,867 18,715 18,581
QALYs 3.891 3.831 3.738 3.796 3.883
ICER vs. PRA-
Driven
Prasugrel
Dominated Dominated Dominated Dominated Dominated
ICER¼incremental cost-effectiveness ratio; QALY¼quality-adjusted life-year; PRA¼platelet
reactivity assay; V¼EurosTCT-162
Universal Versus Platelet Reactivity Assay-Driven Use of P2Y12 Inhibitors in
Acute Coronary Syndrome Patients: Cost-Effectiveness Analyses from Five
European Perspectives
Craig I. Coleman1, Brendan L. Limone1
1University of Connecticut, Hartford, CT
Background: Platelet reactivity assays (PRAs) can predict patients' likely response to
clopidogrel. We assessed the cost-effectiveness of universal compared to PRA-driven
selection of ticagrelor or prasugrel for acute coronary syndrome (ACS) patients living
in multiple European countries.
Methods: An Markov model was used to calculate 5-year costs (2013V), quality-
adjusted life-years and incremental cost-effectiveness ratios (ICERs) for 1-year of
universal ticagrelor or prasugrel (given to all) compared to each agents' corresponding
PRA-driven strategy (ticagrelor/prasugrel in those with high platelet reactivity [HPR,
>208 on the VerifyNow P2Y12 assay, Accumetrics, San Diego, CA], others given
generic clopidogrel]. We assumed patients had their index ACS event at 65-70 years
of age and had a 42.7% incidence of HPR post-revascularization. The analysis was
conducted from the perspective of 5 different European countries (Germany, Italy,
France, Spain and The Netherlands) and used a 1-year cycle length. Efﬁcacy and
safety data for P2Y12 Inhibitors were taken from multinational randomized trials and
adjusted using country-speciﬁc epidemiologic data.
Results: Neither universal ticagrelor nor prasugrel were found to be cost-effective (all
ICERs >40,250V/QALY) compared to their corresponding PRA-driven strategies in
any of the countries evaluated (Table). Results were sensitive to differences in P2Y12
Inhibitors costs and drug-speciﬁc relative risks of major adverse cardiac events. Monte
Carlo simulation suggested universal ticagrelor or prasugrel were cost-effective in
only 29-44% and 11-17% of 10,000 iterations compared to their respective PRA-
driven strategies, when applying a willingness-to-pay threshold¼V30,000/QALY.B52 JACC Vol 62/18/Suppl B j October 27–NovemConclusions: The universal use of newer P2Y12 inhibitors is not likely cost-effective
compared to PRA-driven strategies.
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Background: Paroxysmal atrial ﬁbrillation (AF) is frequent in patients undergoing
percutaneous coronary intervention (PCI), but optimum antithrombotic therapy has
not been deﬁned, and whether patients with paroxysmal AF in sinus rhythm (SR) at
the time of PCI require anticoagulation concurrent with DAPT is unknown.
Methods:We evaluated 291 consecutive patients from 2 university Hospitals (US and
Europe), with paroxysmal non-valvular AF who were in SR at the time of PCI
between 2009 and 2011 prescribed triple (TT, n¼98; 34%) or dual antithrombotic
therapy (DAPT, n¼193; 66%) post PCI and compared rates of major adverse
cardiovascular events (MACCE ¼ death, myocardial infarction [MI], revasculariza-
tion, stroke, peripheral embolism or stent thrombosis) in patients on DAPT (aspirin +
clopidogrel), vs. TT (DAPT + oral anticoagulant).
Results: Baseline characteristics in the TT and DAPT groups were similar for age (72
 9 vs. 70  10 years; P¼0.25), gender (29 vs. 27% females, P¼0.73),
CHA2DS2VASc score >1 (91 vs. 86%, P¼0.25), and ejection fraction <30% (12 vs.
9%, P¼0.34). The TT group had shorter lesions and stents compared to those on
DAPT (25  19 vs. 30  19 mm, P¼0.02). Mean duration of clopidogrel therapy was
similar, as was the use of bare-metal stents. At 1-year, rates of MACCE (22 vs. 20%;
P¼0.71, Figure 1.), stroke (1.2 vs. 0.6%, P¼0.13); major bleeding (3 vs. 1%, P¼0.37)ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMand net adverse cardiac events (25 vs. 21%, P¼0.56) were similar in the TT and
DAPT groups, respectively.
Conclusions: There does not seem to be a signiﬁcant beneﬁt of TT over DAPT in
patients with paroxysmal AF in SR undergoing PCI.P
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Background: The Antagonize P2Y12 Treatment Inhibitors by Transfusion of
platelets in an Urgent or DElayed Timing after ACS or PCI presentation (The
APTITUDE study) was designed to demonstrate the effect of ex vivo platelet
transfusion (PT) in a coronary population receiving loading doses of P2Y12 receptor
antagonists.
Methods: Patients presenting with acute coronary syndrome or for elective PCI and
receiving a loading dose of either clopidogrel 600/900mg, prasugrel 60mg or
ticagrelor 180mg were included. Blood was drawn from participants at two
different time points; just before administration of the P2Y12 inhibitor loading dose
(LD) (H0) and 4-6 hours after (H4). Transfusion was performed ex vivo by mixing
naïve platelets in the form of platelet rich plasma (PRP-H0) with PRP at H4 (PRP-
H4) in increasing proportions. The primary study endpoint was the percentage
restoration of platelet function with addition of 80% proportion of PRP H0
measured by the residual platelet aggregation (RPA) in response to 20 mM ADP
{RPA (80%/20% H0/H4 mix)/RPA baseline x 100} using light transmission
aggregometry.
Results: A total of 56 patients (76% male) half (n¼28) presenting with ACS and half
presenting for elective PCI were included. Baseline RPA did not differ signiﬁcantly
between groups (p¼0.65). Patients with poor pharmacodynamic response to the LD
administered (RPA H4>46.6%) were excluded from the ﬁnal analysis leaving 45
patients: Groups 1. clopidogrel 600mg (n ¼13) 2. clopidogrel 900mg (n¼12) 3.
prasugrel 60mg (n¼10) 4. ticagrelor 180mg (n¼10). Increasing proportions (30%,
50%, 80%) of platelet transfusion led to a stepwise increase in restoration of platelet
reactivity in all groups 1-4 (p for trend < 0.0001, 0.01, <0.0001 and 0.0052
respectively). The primary endpoint of % restoration of platelet function with 80%
proportion PT showed a stepwise decrease from groups 1 to 4 (83.911%, 7314%,
66.315%, 40.919% respectively; p for trend < 0.0001).
Conclusions: The efﬁcacy of ex vivo platelet transfusion in normalization of platelet
function appears to decrease with more potent P2Y12 receptor antagonism and to be
the least with direct P2Y12 inhibitors.
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Background: Data on direct pharmacodynamic comparison between ticagrelor and
prasugrel are limited, mainly involving speciﬁc subgroups (e.g. patients with STJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrelevation myocardial infarction-STEMI, diabetes mellitus or high platelet reactivity
under clopidogrel).
Methods: This was a prospective, single-center study, in consecutive patients with
acute coronary syndrome (ACS), who underwent percutaneous coronary intervention
(PCI). Platelet reactivity (PR) measurement was performed 30 days after constant
treatment with ticagrelor 90mg bid or prasugrel 10mg od maintenance dose. Treatment
choice was at physicians' discretion. Bleeding events (Bleeding Academic Research
Consortium –BARC classiﬁcation) were also monitored.
Results: We recruited 384 patients (with a mean age of 59.311.1 years, 83.6% men,
24.5% diabetics and 55.7% admitted with STEMI), out of them 211 and 173 received
ticagrelor and prasugrel respectively. Demographic and angiographic characteristics of
patients were well balanced between groups. After propensity score adjustment for
gender, diabetes mellitus, smoking, creatinine clearance<60ml/min, age, hematocrit,
platelet count and body mass index, PR at 30 days was signiﬁcantly lower with
ticagrelor compared with prasugrel (34.4, 95%CIs 28.2-40.7 versus 81.9, 95%CIs
74.9-88.8, p<0.001). There was a trend towards more BARC type 1 events with
ticagrelor compared to prasugrel at 30 days (38.9% vs 29.5%, p¼0.07). However,
BARC type 2 events did not differ between ticagrelor and prasugrel (1.4% vs 2.9%,
p¼0.5).
Conclusions: In patients with ACS undergoing PCI, ticagrelor MD produces
a signiﬁcantly higher platelet inhibition compared to prasugrel MD. This observed
pharmacodynamic difference might be associated with more nuisance bleeding events
with ticagrelor use.TCT-166
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Background: Several studies have demonstrated an association between high
platelet reactivity (HPR) on clopidogrel and the risk of stent thrombosis and adverse
ischemic outcomes. We sought to determine the correlates of HPR from a large
observational study of patients undergoing routine platelet reactivity testing.
Methods: ADAPT-DES was a prospective multicenter study of pts treated with
coronary DES designed to determine the predictors of stent thrombosis. VerifyNow
P2Y12 testing was performed after clopidogrel loading in 8,583 "all-comer" pts
enrolled at 11 international sites. Linear regression of platelet reactivity units (PRU)
on baseline and procedural covariates was used to determine independent correlates of
PRU.
Results: The mean age was 63.6 years, an acute coronary syndrome was present in
51.7% of pts, and the mean PRU was 188  97. Baseline demographic charac-
teristics independently associated with higher PRU included: age, body mass index,
female sex, non-Caucasian ethnicity, diabetes, non-smoking status, prior myocar-
dial infarction, and anemia. Pre-hospital use of a thienopyridine or statin was
independently associated with higher PRU. When procedural characteristics were
examined in addition to baseline covariates, use of femoral vascular access, intra-
aortic balloon pump, and bivalirudin for anticoagulation were all independently
associated with higher PRU, as were baseline TIMI 0/1 ﬂow, total stent length, and
treatment of calciﬁc lesions. Further modeling to identify the percent contribution
of each of these covariates to the overall variance of PRU will be performed/
presented.
Conclusions: In a large unselected cohort of patients undergoing PCI with DES,
numerous independent correlates of HPR were identiﬁed, including demographic
characteristics, comorbid conditions, antecedent medications, and procedural vari-
ables. These ﬁndings illustrate the multifactorial nature of clopidogrel responsiveness
among patients undergoing PCI.acts/POSTER/Antiplatelets and Antithrombins B53
